Premium
Pharmacokinetics of 13C‐Lycopene in Healthy Adults
Author(s) -
Moran Nancy E,
Cichon Morgan J.,
Riedl Kenneth M.,
Grainger Elizabeth M.,
Schwartz Steven J.,
Erdman John W.,
Clinton Steven K.
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.38.6
Subject(s) - pharmacokinetics , chemistry , bioavailability , lycopene , high performance liquid chromatography , dosing , plasma concentration , pharmacology , chromatography , carotenoid , biochemistry , medicine , organic chemistry
Higher plasma lycopene (LYC) concentrations are associated with lower risk of several cancers. (All‐ E )‐LYC is the predominant geometrical isomer in tomatoes, yet most plasma and tissue LYC isomers are Z , suggesting greater bioavailability of Z and/or endogenous isomerization of E to Z . To study human LYC pharmacokinetics and isomerization, ~10 mg of 13 C‐LYC isolated from tomato cell cultures was consumed with breakfastby 6 healthy adults. The dose was 85% (all‐ E )‐LYC, and ~30% uniformly labeled. Plasma was collected at 1–10, 24, 72, and 672 hrs post‐dosing. Native and 13 C‐LYC was analyzed by HPLC‐PDA, and LC‐MS (QToF), respectively. No adverse effects of 13 C‐LYC were observed. 13 C‐LYC C max = 0.13±0.03 μM which occurred at 32±8 hr, T 1/2 = 6.5 ± 0.3 d, and area‐under‐the‐curve (AUC 0–672 ) = 36.9±7 μM*h. Plasma 13 C‐all‐ E ‐LYC C max =0.10 ±0.02 μM at 29±9 h post‐dosing, T 1/2 = 5.5±0.3 d, and it constituted 67% of total 13 C‐LYC AUC. Total 13 C‐ Z ‐LYC isomers C max =0.03 ± 0.005 μM at 56±10 hr post‐dosing with a subsequent T 1/2 = 9.3±0.6 days, and constituted 32% of the total 13 C‐LYC AUC. Initial plasma 13 C‐LYC was 73–87% all‐ E , but by 672 hr, had decreased to 46%. The later Z isomer C max and longer T 1/2 relative to all‐ E suggests that endogenous conversion is a source of circulating Z ‐LYC isomers. Understanding LYC pharmacokinetics assists in designing anti‐cancer dietary interventions. Grant Funding Source : NCCAM R21AT005166, Pelotonia, OSUCCC NPASR